GLP-1 Drugs Threaten Snack Giants

The rapid proliferation of GLP-1 weight-loss drugs has led to a significant transformation in the snack industry by changing consumers' eating habits. Individuals using these drugs snack less and reduce spending at restaurants and grocery stores, creating a multibillion-dollar risk for industry giants. Major companies such as PepsiCo and Kroger are directly affected by these changing consumer behaviors. The growing popularity of GLP-1 drugs could pressure the financial performance of these companies in the coming years. Industry analysts suggest that snack and retail giants may struggle to adapt to this new reality and could even face bankruptcy risk. This structural change in consumer spending requires companies to reconsider their business models. Not investment advice.

📊 MDLZ — Piyasa Yorumu

▼ down · 55%

News that GLP-1 drugs will reduce snack consumption signals a negative demand risk for companies like MDLZ. Technical indicators are already weak: the price is below the 20- and 50-day moving averages, MACD is negative, and RSI at 46 is in neutral-weak territory. This news could increase selling pressure in the short term, but the magnitude of the impact is uncertain. In the 1-3 day outlook, downside risk outweighs, but volume and additional news flow should be monitored for a definitive decline.

RSI 14

46.2

MACD

-0.04

24h Δ

-0.27%

📊 PEP — Piyasa Yorumu

▼ down · 60%

PEP stock is under selling pressure following news that GLP-1 drugs could reduce snack consumption. The price at 133.61 is below the SMA20 and SMA50, with RSI at 35 confirming weak momentum. MACD is negative and below the signal line, supporting a short-term bearish trend. The news is a direct catalyst and could heighten perceptions of structural risk in the sector. A downward move is more likely within 1-3 days, but oversold conditions could lead to limited buying interest.

RSI 14

35.2

MACD

-0.71

24h Δ

-2.08%

📊 KR — Piyasa Yorumu

■ neutral · 35%

News that GLP-1 drugs may reduce snack consumption poses a medium-term risk for food retailers, but KR (Kroger), as a grocery chain, has a different business model from snack manufacturers. Technical indicators are mixed: RSI is neutral around 50, MACD is below the signal line, and the price is slightly below the 20-day moving average but above the 50-day moving average. The news may have limited short-term (1-3 day) price impact; the market may have already priced in this theme. Therefore, the direction is uncertain, and a neutral stance is appropriate.

RSI 14

50.5

MACD

0.24

24h Δ

0.00%

📊 HSY — Piyasa Yorumu

▼ down · 60%

HSY stock is under selling pressure following news that GLP-1 drugs could reduce snack consumption. The price is at 168.32, below the SMA20 and SMA50, with RSI at 33, near oversold territory but no reversal signal yet. MACD is negative and below the signal line, indicating weak short-term momentum. The news is perceived as a sector threat and could sustain downward pressure over the next 1-3 days. However, the low RSI level may limit sharp declines, so a cautious bearish outlook prevails.

RSI 14

33.0

MACD

-0.97

24h Δ

-3.08%

Canlı Grafikler